SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination With Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging
Latest Information Update: 08 May 2025
At a glance
- Drugs Irinotecan (Primary) ; Trabectedin (Primary) ; F-18 fluorothymidine
- Indications Ewing's sarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms SARC037
Most Recent Events
- 29 Apr 2025 Status changed from active, no longer recruiting to completed.
- 06 Dec 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.
- 06 Dec 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2025.